According to the American Heart Association, coronary heart disease (CHD) caused one out of every five deaths in the US in 2002. However, the majority of CHD is preventable. Screening, lifestyle changes and drug therapy can reduce an individuals risk of CHD. This is particularly important where there is a clustering of risk factors in the same individual as seen in metabolic syndrome patients

Scope

Understand the definition of atherosclerosis, its epidemiology, mortality statistics and the burden on healthcare spending
Understand the risk factors which can be changed or treated to reduce the risk of atherosclerotic disease
Learn about risk factor screening, global risk estimation and risk intervention measures including therapeutic lifestyle changes and drug therapy
Appreciate the possibility of multiple risk factors being present in one individual as metabolic syndrome and the link to coronary heart disease

Report Highlights

Cardiovascular disease is the leading cause of mortality in the US and Europe. More than one in five deaths are from coronary heart disease (CHD). Moreover the cost of CHD is huge. The American Heart Association, estimates the cost will be $142 billion in 2005 and the British Heart Foundation estimates it costs the UK almost $14 billion per year

The majority of heart disease is preventable through education and identification of risk factors. These include hypertension, hypercholesterolemia, being overweight/obese, diabetes mellitus, smoking and physical inactivity. Guidelines promote a healthy diet, weight loss and physical activity, although drug therapy is recommended where insufficient

Metabolic syndrome is characterized by a cluster of risk factors in one individual. Central obesity and insulin resistance are considered important causative factors. This combination leads to a high risk of type 2 diabetes and cardiovascular disease with an accepted increase in risk of between 1.5 and two times

Reasons to Purchase

Acquire data on the epidemiology of coronary heart disease to enable sizing of the market opportunity
Understand how to target your product portfolio to the risk factors associated with coronary heart disease
Understand the potential market in metabolic syndrome patients of targeting multiple risk factors in the same individual

ABOUT DATAMONITOR HEALTHCARE

About the Cardiovascular pharmaceutical analysis team

EXECUTIVE SUMMARY

Introduction
Scope and coverage of the Brief
Key findings

ATHEROSCLEROSIS OVERVIEW

Disease definition
Epidemiology
Burden of atherosclerosis and coronary heart disease

Mortality
Cost

PREVENTION OF ATHEROSCLEROSIS

Atherosclerotic risk factors

Hypertension
Hypercholesterolemia
Overweight and obesity
Diabetes
Smoking

AHA recommendations for the prevention of coronary heart disease

Risk factor screening
Global risk estimation
Risk intervention

Blood pressure control
Blood lipid management
Weight management
Dietary intake
Physical activity
Smoking
Aspirin
Diabetes mellitus

Therapeutic lifestyle changes
Drug therapy

Antihypertensives
Statins
Obesity drugs
Antidiabetics

Metabolic syndrome

Metabolic syndrome definition
Clinical criteria for diagnosis
Metabolic syndrome and coronary heart disease

APPENDIX

Bibliography

Research methodology
Disclaimer

List of Tables

Table 1: Epidemiology of cardiovascular disease, coronary heart disease and stroke in the US in 2002
Table 2: Disability and mortality burdens of heart disease and stroke in the seven major markets in 2002
Table 3: ATP III diagnostic criteria for metabolic syndrome
Table 4: WHO working criteria for metabolic syndrome
Table 5: IDF diagnostic criteria for metabolic syndrome